Portal de Periódicos da CAPES

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

2011; Springer Science+Business Media; Volume: 30; Issue: 6 Linguagem: Inglês

10.1007/s10637-011-9765-7

1573-0646

Jason Konner, Rachel N. Grisham, Jae H. Park, Owen A. O’Connor, G. Cropp, Robert G. Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Miranov, Samuel J. Danishefsky, David M. Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian,

Glioma Diagnosis and Treatment

Purpose To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma. Patients and Methods Patients were treated weekly for 3 out of 4 weeks (Schedule A) or 2 out of 3 weeks (Schedule B) with KOS-862 (16–120 mg/m2). Pharmacokinetic (PK) sampling was performed during cycles 1 and 2; pharmacodynamic (PD) assessment for microtubule bundle formation (MTBF) was performed after the 1st dose, only at or above 100 mg/m2. Results Thirty-two patients were enrolled, and twenty-nine completed ≥1 cycle of therapy. Dose limiting toxicity [DLT] was observed at 120 mg/m2. PK data were linear from 16 to 100 mg/m2, with proportional increases in mean Cmax and AUCtot as a function of dose. Full PK analysis (mean ± SD) at 100 mg/m2 revealed the following: half-life (t ½) = 9.1 ± 2.2 h; volume of distribution (Vz) = 119 ± 41 L/m2; clearance (CL) = 9.3 ± 3.2 L/h/m2. MTBF (n = 9) was seen in 40% of PBMCs within 1 h and in 15% of PBMC at 24-hours post infusion at 100 mg/m2. Tumor shrinkage (n = 2, lymphoma), stable disease >3 months (n = 5, renal, prostate, oropharynx, cholangiocarcinoma, and Hodgkin lymphoma), and tumor marker reductions (n = 1, colorectal cancer/CEA) were observed. Conclusion KOS-862 was well tolerated with manageable toxicity, favorable PK profile, and the suggestion of clinical activity. The maximum tolerated dose was determined to be 100 mg/m2 weekly 3-on/1-off. MTBF can be demonstrated in PBMCs of patients exposed to KOS-862.